Receive our newsletter – data, insights and analysis delivered to you
June 22, 2009

BioLineRx Antipsychotic Drug Shows Good Results

The latest results for BioLineRx's new-generation antipsychotic BL-1020 for the treatment of schizophrenia show a reversal of cognitive impairment with minimal side effects and greater tolerability. BL-1020 is an orally available antipsychotic for the treatment of schizophrenia. It has

By cms admin

The latest results for BioLineRx’s new-generation antipsychotic BL-1020 for the treatment of schizophrenia show a reversal of cognitive impairment with minimal side effects and greater tolerability.

BL-1020 is an orally available antipsychotic for the treatment of schizophrenia. It has recently completed a Phase IIb clinical trial, designed to assess performance in two distinct cognitive domains.

Recent pre-clinical studies show that BL-1020 reverses cognitive impairment and that this reversal is mediated by the GABA moiety of BL-1020.

BioLineRx CEO Morris Laster said that these results are extremely important for the confirmation of the mode of action of BL-1020 in reducing EPS and improving cognition.

“These results showing improved cognition may also allow for increased indication coverage for BL-1020 including dementia associated with Parkinson’s and even as a potential adjunct treatment for Alzheimer’s,” Laster said.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU